Clinical Trial Update: Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Interleukin-21 for metastatic malignant melanoma and metastatic kidney cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• Interleukin-21 (Interleukin-21)

Snippet

Sponsor: ZymoGenetics | Conditions: Melanoma, Kidney Neoplasms | Phase 1 | Status: COMPLETED